Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
NCT07674368
·
clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
29
Enrollment
OTHER
Sponsor class
Conditions
ALK Fusion-positive Non-small Cell Lung Cancer
Interventions
DRUG:
Recaticimab
Sponsor
Hunan Cancer Hospital